Literature DB >> 15046723

Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures.

Patrick H N Celie1, Sarah E van Rossum-Fikkert, Willem J van Dijk, Katjusa Brejc, August B Smit, Titia K Sixma.   

Abstract

Nicotinic acetylcholine receptors are prototypes for the pharmaceutically important family of pentameric ligand-gated ion channels. Here we present atomic resolution structures of nicotine and carbamylcholine binding to AChBP, a water-soluble homolog of the ligand binding domain of nicotinic receptors and their family members, GABAA, GABAC, 5HT3 serotonin, and glycine receptors. Ligand binding is driven by enthalpy and is accompanied by conformational changes in the ligand binding site. Residues in the binding site contract around the ligand, with the largest movement in the C loop. As expected, the binding is characterized by substantial aromatic and hydrophobic contributions, but additionally there are close contacts between protein oxygens and positively charged groups in the ligands. The higher affinity of nicotine is due to a main chain hydrogen bond with the B loop and a closer packing of the aromatic groups. These structures will be useful tools for the development of new drugs involving nicotinic acetylcholine receptor-associated diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15046723     DOI: 10.1016/s0896-6273(04)00115-1

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  336 in total

1.  A force field with discrete displaceable waters and desolvation entropy for hydrated ligand docking.

Authors:  Stefano Forli; Arthur J Olson
Journal:  J Med Chem       Date:  2012-01-13       Impact factor: 7.446

Review 2.  Synaptic neurotransmitter-gated receptors.

Authors:  Trevor G Smart; Pierre Paoletti
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-03-01       Impact factor: 10.005

3.  Enhanced meta-analysis of acetylcholine binding protein structures reveals conformational signatures of agonism in nicotinic receptors.

Authors:  Spencer T Stober; Cameron F Abrams
Journal:  Protein Sci       Date:  2012-03       Impact factor: 6.725

Review 4.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

5.  Rapid desensitization of the rat α7 nAChR is facilitated by the presence of a proline residue in the outer β-sheet.

Authors:  Thomas J McCormack; Claudio Melis; José Colón; Elaine A Gay; Arpad Mike; Robert Karoly; Patricia W Lamb; Carla Molteni; Jerrel L Yakel
Journal:  J Physiol       Date:  2010-09-13       Impact factor: 5.182

Review 6.  Structures of membrane proteins.

Authors:  Kutti R Vinothkumar; Richard Henderson
Journal:  Q Rev Biophys       Date:  2010-02       Impact factor: 5.318

Review 7.  Molecular mechanisms of acetylcholine receptor-lipid interactions: from model membranes to human biology.

Authors:  John E Baenziger; Corrie J B daCosta
Journal:  Biophys Rev       Date:  2012-05-10

8.  Pentameric ligand-gated ion channel ELIC is activated by GABA and modulated by benzodiazepines.

Authors:  Radovan Spurny; Joachim Ramerstorfer; Kerry Price; Marijke Brams; Margot Ernst; Hugues Nury; Mark Verheij; Pierre Legrand; Daniel Bertrand; Sonia Bertrand; Dennis A Dougherty; Iwan J P de Esch; Pierre-Jean Corringer; Werner Sieghart; Sarah C R Lummis; Chris Ulens
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-03       Impact factor: 11.205

9.  Aromatic Residues {epsilon}Trp-55 and {delta}Trp-57 and the Activation of Acetylcholine Receptor Channels.

Authors:  Pallavi A Bafna; Archana Jha; Anthony Auerbach
Journal:  J Biol Chem       Date:  2009-01-26       Impact factor: 5.157

10.  Tyrosine residues that control binding and gating in the 5-hydroxytryptamine3 receptor revealed by unnatural amino acid mutagenesis.

Authors:  Darren L Beene; Kerry L Price; Henry A Lester; Dennis A Dougherty; Sarah C R Lummis
Journal:  J Neurosci       Date:  2004-10-13       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.